0001225208-20-002621.txt : 20200218
0001225208-20-002621.hdr.sgml : 20200218
20200218162115
ACCESSION NUMBER: 0001225208-20-002621
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200217
FILED AS OF DATE: 20200218
DATE AS OF CHANGE: 20200218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scanlon Meghan
CENTRAL INDEX KEY: 0001801586
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 20625579
MAIL ADDRESS:
STREET 1: C/O BOSTON SCIENTIFIC CORPORATION
STREET 2: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
3
1
doc3.xml
X0206
3
2020-02-17
0
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001801586
Scanlon Meghan
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH
MA
01752-1234
1
SVP,Pres,Urology Pelvic Health
Common Stock
7321.0000
D
Deferred Stock Units
2023-02-15
Common Stock
3323.0000
D
Deferred Stock Units
2023-02-21
Common Stock
3115.0000
D
Deferred Stock Units
2021-02-22
Common Stock
2318.0000
D
Deferred Stock Units
2020-02-23
Common Stock
1227.0000
D
Deferred Stock Units
2022-02-28
Common Stock
3055.0000
D
Deferred Stock Units
2023-05-01
Common Stock
8246.0000
D
Deferred Stock Units
2021-07-01
Common Stock
1709.0000
D
Stock Option (Right to Buy)
17.2600
2026-02-22
Common Stock
16450.0000
D
Stock Option (Right to Buy)
23.4100
2026-07-01
Common Stock
13850.0000
D
Stock Option (Right to Buy)
24.5500
2027-02-28
Common Stock
18037.0000
D
Stock Option (Right to Buy)
27.0900
2028-02-15
Common Stock
18007.0000
D
Stock Option (Right to Buy)
40.1200
2029-02-21
Common Stock
10757.0000
D
Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 15, 2018, which will continue to vest in three remaining installments on the anniversary of the date of grant.
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 22, 2016, which will continue to vest in two remaining installments on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 23, 2015, which will continue to vest in one remaining installment on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 28, 2017, which will continue to vest in three remaining installments on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on July 1, 2016, which will continue to vest in two remaining installments on the anniversary of the date of grant.
Grant to the reporting person of an option to purchase 18,450 shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 13,850 shares of common stock vesting in four equal annual installments beginning on July 1, 2017, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 18,037 shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 18,007 shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase 10,757 shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
scanlonpoa.txt
/s/ Scott G. Hodgdon, Attorney-in-Fact
2020-02-18
EX-24
2
scanlonpoa.txt
POWER OF ATTORNEY
Know all by these present that the undersigned hereby constitutes and
appoints each of Desiree Ralls-Morrison, Vance R. Brown, Scott Hodgdon, Ashley
E.
McGrane and Mai-Khoi Nguyen-Thanh signing singly, the undersigned's true and
lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an executive officer and/or director of Boston Scientific
Corporation
(the "Company"), Forms 3, 4 and 5, and amendments thereto, in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5
and file such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority;
(3) execute for and on behalf of the undersigned, in the undersigned's capacity
as an executive officer and/or director of the Company, Forms 144 in accordance
with Rule 144 of the Securities Exchange Act of 1933, as amended and the rules
and regulations thereunder; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might
or could do if personally present, with full power of substitution or
revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities
Act of 1933, as amended.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with
respect to the undersigned's holdings of and transactions in securities issued
by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 28th of January, 2020.
/s/ Meghan Scanlon
________________
Meghan Scanlon